Shows long-term efficacy of dostarlimab in patients with dMMR/MSI-H endometrial cancer, suggesting potential for improved outcomes.
The GARNET trial is the largest trial of an anti-PD-1 monotherapy, dostarlimab, in patients with dMMR/MSI-H advanced/recurrent (A/R) EC after platinum-based chemotherapy and supported global approvals in this setting. Previously published results provided robust evidence of clinical benefit and demonstrated durable antitumor activity with an acceptable safety profile. Here we report updated efficacy and safety at 6y follow-up accompanied by a conditional survival analysis to provide prognostic insights into long-term survival potential.
No takes yet. Share an insight, caveat, or question.
Oaknin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: